Connect with us

Lifestyle

The UN approves a second malaria vaccine. Experts caution that preventing the spread of the disease alone is insufficient.

Published

1 year ago

on

The UN approves a second malaria vaccine. Experts caution that preventing the spread of the disease alone is insufficient.

The UN Approves a Second Malaria Vaccine: A Milestone in the Fight Against a Deadly Disease

Malaria, a mosquito-borne infectious disease caused by the Plasmodium parasite, has plagued humanity for centuries, particularly in sub-Saharan Africa. The World Health Organization (WHO) estimates that in 2020 alone, there were approximately 241 million malaria cases worldwide, leading to an estimated 627,000 deaths, primarily among children under five years of age. Malaria’s impact on global health and economies has been devastating, making it a significant public health concern. Recently, the United Nations (UN) approved a second malaria vaccine, marking a milestone in the battle against this deadly disease. However, experts caution that preventing the spread of malaria requires a multi-faceted approach beyond just vaccination.

The Challenge of Malaria

Advertisement

Malaria is a complex disease that poses significant challenges to eradication efforts. The parasite’s ability to develop resistance to antimalarial drugs and the adaptability of its mosquito vector make it a formidable adversary. Furthermore, many affected regions lack adequate healthcare infrastructure, making the delivery of prevention and treatment measures difficult.

The First Malaria Vaccine: A Step Forward

In 2015, the world saw the first-ever malaria vaccine, known as RTS,S/AS01 (trade name Mosquirix), receive regulatory approval. Developed by GlaxoSmithKline (GSK) in partnership with the PATH Malaria Vaccine Initiative, this vaccine showed promise in reducing the risk of malaria in children. While a significant advancement, it had limitations, such as being less effective in areas with high malaria transmission rates.

A New Hope: The Second Malaria Vaccine

Advertisement

The recent approval of a second malaria vaccine, known as R21/Matrix-M, has reignited hope in the fight against the disease. Developed by the University of Oxford’s Jenner Institute in collaboration with Novavax and the Serum Institute of India, this vaccine has shown remarkable efficacy in clinical trials. It demonstrated an ability to reduce the risk of malaria by approximately 77% over 12 months, making it a significant breakthrough.

The Multifaceted Approach to Malaria Eradication

While the approval of a second malaria vaccine is undoubtedly a positive development, experts emphasize that it’s not a panacea for malaria eradication. Preventing the spread of the disease requires a multi-pronged approach that includes:

  1. Vector Control: Mosquito control measures, such as bed nets treated with insecticides and indoor residual spraying, remain essential in reducing malaria transmission.
  2. Effective Treatment: Access to prompt and effective treatment with antimalarial drugs is critical for those who contract the disease.
  3. Public Health Infrastructure: Strengthening healthcare systems in affected regions to provide proper diagnosis and treatment is crucial.
  4. Education and Awareness: Public awareness campaigns can help communities understand the importance of preventive measures and early treatment.
  5. Research and Innovation: Ongoing research into malaria prevention, treatment, and vector control is vital to stay ahead of the evolving parasite.

Conclusion

The approval of a second malaria vaccine by the UN is undoubtedly a significant stride in the fight against this deadly disease. However, experts caution that a comprehensive approach, encompassing vaccination, vector control, treatment, healthcare infrastructure, education, and research, is necessary to make substantial progress toward malaria eradication. With continued global efforts and investments, we can hope for a future where malaria is no longer a threat to millions of lives worldwide.

Advertisement

Group Media Publications
Entertainment News Platforms – anyflix.in      
Construction Infrastructure and Mining News Platform – https://cimreviews.com/
General News Platform – https://ihtlive.com/
Podcast Platforms – https://anyfm.in

Related Topics:
Continue Reading

Music

NewJeans’ Hanni gets reported as Illegal immigrant to customs amid ADOR contract termination: Report

Published

1 day ago

on

December 21, 2024

By

NewJeans’ Hanni gets reported as Illegal immigrant to customs amid ADOR contract termination: Report

NewJeans has ended its contract with ADOR, leading to potential legal troubles for member Hanni regarding her visa status.
NewJeans members have recently terminated their contract with their management agency, ADOR, though the agency maintains that the contract remains valid. While the group is now operating independently, at least from their perspective, new troubles are looming. On December 20, 2024, 10Asia reported that NewJeans’ member Hanni was reported as an illegal immigrant to South Korean Customs.

NewJeans’ Hanni reported as an Illegal immigrant

According to the reports, an unidentified individual filed a complaint, demanding her deportation. Hanni holds dual citizenship requiring her to renew her visa in South Korea annually. Earlier, rumors circulated about Hanni’s visa expiring soon. However, ADOR previously stated they were preparing to extend her visa as usual, since they don’t acknowledge the contract termination. This suggests no immediate visa issues for Hanni or the group.

However, the situation has become more complicated since NewJeans publicly announced their contract termination. Legal experts believe that if the group continues to operate independently, Hanni’s visa, which was initially granted through ADOR, could become invalid.

Advertisement

Out of the five members, Daniel has dual citizenship in Korea and Australia, so she’s all good. But Hanni, who holds dual citizenship in Australia and Vietnam, is definitely considered a foreigner and needs to get visa extensions every year.

If Hanni’s contract with Adore was indeed terminated on the 29th of last month, her visa would no longer be valid and she could be considered an illegal resident. Under the Immigration Control Act, she should have left South Korea by the 13th of this month. Since Adore claims the contract is still valid, it’s unlikely they would consent to a visa transfer under the act that allows people to change workplaces without needing a new visa, but the agency they work with must agree to the change.

What is an E6 visa in South Korea?

Foreign entertainers in South Korea typically rely on E-6 visas, sponsored by their management agencies. These visas allow them to work in the country. E6 is typically issued to entertainers, artists, and athletes. However, if the contract with the agency ends, the visa can become invalid.

Since NewJeans has announced its intention to leave ADOR, Hanni may need to find a new agency to sponsor her visa or face the possibility of having to leave South Korea.

Advertisement

Hanni has the option to renew her E-6 visa by signing with a new agency; however, immigration law requires that she obtain approval from her previous agency first. At the same time, HYBE, the parent company of ADOR, has been in conflict with the former CEO of its subsidiary, Min Hee Jin, for several months, which has unfortunately impacted NewJeans. Since ADOR is disputing the termination and pursuing legal action, it is unlikely that they will grant the necessary approval for Hanni’s visa renewal.

South Korean immigration law also requires individuals to apply for a visa change or secure a new contract within 15 days of termination, which has already passed. The last option for Hanni is to leave South Korea and apply for a new E-6 visa abroad.

Group Media Publications
Entertainment News Platforms – anyflix.in      
Construction Infrastructure and Mining News Platform – https://cimreviews.com/
General News Platform – https://ihtlive.com/

Advertisement
Continue Reading
Anyskill-ads

Facebook

Trending